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Abstract
Background: The CCL2 chemokine is involved in promoting cancer angiogenesis, proliferation and metastasis by
malignancies that express CCR2 receptor. Thus the CCL2/CCR2 axis is an attractive molecular target for anticancer
drug development.
Methods: We have generated a novel fusion protein using GMCSF and an N-terminal truncated version of MCP1/
CCL2 (6-76) [hereafter GMME1] and investigated its utility as a CCR2-specific tumoricidal agent.
Results: We found that distinct to full length CCL2 or its N-truncated derivative (CCL2 5-76), GMME1 bound to
CCR2 on mouse lymphoma EG7, human multiple myeloma cell line U266, or murine and human medulloblastoma
cell lines, and led to their death by apoptosis. We demonstrated that GMME1 specifically blocked CCR2-associated
STAT3 phosphorylation and up-regulated pro-apoptotic BAX. Furthermore, GMME1 significantly inhibited EG7
tumor growth in C57BL/6 mice, and induced apoptosis of primary myeloma cells from patients.
Conclusion: Our data demonstrate that GMME1 is a fusokine with a potent, CCR2 receptor-mediated pro-apoptotic
effect on tumor cells and could be exploited as a novel biological therapy for CCR2+ malignancies including
lymphoid and central nervous system malignancies.
Background
CC Chemokines and their cognate receptors are involved in
the proliferation and metastasis of several tumors [1]. The
CCL2/CCR2 axis is a direct example as highlighted by
CCL2-driven proliferation and survival of hematological
[2,3] and solid tumors [4,5]. Thus, inhibiting CCL2 or its
receptor may allow a direct interference with tumor biology.
As an alternative to the development of neutralizing or
antagonizing antibodies, our group has focussed on the
engineering of bifunctional proteins borne from the
fusion of two biologically distinct cytokines [6-12]. These
fusokines have been shown to lead to novel unheralded
pharmacological effects including potent, receptor-speci-
fic antitumor effects [6,11]. Interestingly, granulocyte
macrophage-colony stimulating factor (GMCSF)-based
fusokines may either lead to pro-inflammatory synergy or
profoundly antagonistic properties depending on the
influence played by the GMCSF moiety of the fusokine
on the C-terminal partner signalling pathway.
The previously described GMME1 fusion protein,
composed of mouse GM-CSF and truncated CCL2 (6-
76) missing the first 5 N-terminal amino-acids, binds to
CCR2 and initiates an aberrant signalling cascade which
activates a pro-apoptotic response associated with cal-
cium flux, dephosphorylation of STAT3 and decreased
pAKT (Figure 1A) [10,11].
We here report its use as a cancer therapeutic agent
targeting tumors expressing CCR2 and provide pre-clini-
cal evidence that this pro-apoptotic fusokine could be of
great interest as a lead compound of a new class of bio-
logical agents targeting CCR2-expressing malignancies.
Methods
Mice, cell lines and reagents
All mice used were 6-8 week old C57Bl/6 females (Jack-
son Laboratory, Bar Harbor, ME). All experimental
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protocols were approved by the animal ethic committee
of the Lady Davis Institute of McGill University. The
mouse T-cell lymphoma cell line EG.7 (EL4 cells trans-
fected to express chicken ovalbumin), human medullo-
blastoma cell line Daoy, and the human myeloma cell
line U266 were purchased from ATCC (VA, USA) and
propagated according to manufacturer’s instructions.
The murine medulloblastoma cell line PS125 was estab-
lished from medulloblastomas derived from the Smo/
Smo transgenic mouse [13] and propagated in DMEM/
F-12 supplemented with 10% FBS, 1% L-glutamine, 1%
MEM non-essential amino acids, and 1% N-2 at 37°C in
5% CO2. Antibodies for CD19, CD44, CD45, CD73,
CD105 and CD138 were purchased from BD Biosciences
(San Diego, CA). Mouse recombinant CCL2 protein
(CCL2 1-76), ELISA kits for mouse CCL2 and human
IL6, anti-human CCR2 antibody, CCR2 primers, and
Annexin-V/PI detection kits were purchased from R&D
systems (Minneapolis, USA). Antibody for a-tubulin
was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies for BAX, pSTAT3 and total
STAT3 were purchased from Cell Signalling Technology
(Danvers, MA). RNA extraction kit was purchased from
Qiagen (Mississauga, ON, CANADA). Contigen was
purchased from Bard Urological Division (Covington,
GA, USA). The 5-76 variant (CCL2 5-76) of murine
CCL2 was synthesized from Genecust (Dudelange, Lux-
embourg). The monocyte enrichment kit was purchased
from StemCell Technologies (Vancouver, Canada).
Isolation and characterization of mouse mesenchymal
stromal cells
Whole bone marrow was harvested by flushing femurs
and tibias bones of female CCL2-/- C57BL/6 mice with
DMEM. Collected cells were plated and cultured until
the appearance of a homogeneous polyclonal population
of mesenchymal stromal cells (MSC). The plasticity of
isolated MSCs was tested as previously reported [14].
For CCR2 expression on MSC, RT-PCR was performed
on extracted RNA using purchased primers.
Engineering CCL2-/-MSC to express GMME1
We have previously demonstrated that wild-type MSCs
could generate in a paracrine fashion truncated CCL2
(5-76) capable of antagonizing CCR2-expressing cells
[15]. Therefore, CCL2-/-MSCs were used in this study to
avoid any confounding effects arising from endogenous
MSC production of CCL2 and derivatives. The genera-
tion and concentration of green fluorescent protein
(GFP) or GMME1 retroparticles using the bicistronic
AP2 vector were generated as previously reported [6].
The level of GMME1 expression was analyzed through
the assessment of GFP by flow cytometry, while
GMME1 secretion level in the harvested DMEM
conditioned medium was quantified using a CCL2
ELISA kit. Alternatively, GMME1 protein was purified
from the conditioned medium with an affinity column
(Pierce Biotechnology, Rockford, USA, Kit # 26148)
loaded with anti-mouse GM-CSF antibodies (R&D, Min-
neapolis, USA) by following the instruction described in
the kit. The purified GMME1 protein was dialyzed with
fresh DMEM medium, and concentrated for use.
Biochemical analyses
To test the proliferative property of GMME1, the mouse
lymphoma EG7 or human multiple myeloma U266 cell
lines were plated at a density of 105 cells/well in a 96-
well plate and treated with increasing concentrations of
cytokines for 48 hours. The reaction was read at 570
nm after adding 20 μL of 3-(4,5-dimethylhiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT). For Apoptosis
analysis, the mouse EG7 or human U266 cell lines were
cultured for 48 hrs with equimolar concentrations (1.5
pmol) of CCL2 (1-76), CCL2 (5-76), or GMME1 then
analyzed by PI/Annexin-V. WT and CCR2-/- monocytes
were enriched to 90% purity using negative selection fol-
lowing the bone marrow flush of femurs and tibias. Pur-
ified cells were then cultured for 48 hrs in control or
GMME1 supernatant. A cell-killing assay was also per-
formed on two medulloblastoma cell lines PS125
(mouse-derived) and Daoy (human-derived), treated
with or without GMME1 for 48 hrs and cell death mea-
sured by flow-cytometry using PI and Annexin-V. Alter-
natively, Daoy cells were also treated with GMME1 in
conditioned medium or affinity-purified GMME1 pro-
tein, and the cell growth was assessed by MTT assay.
Western blot was performed on the lysate derived from
treated cell lines probed with anti-BAX antibodies, or
anti-pSTAT3 or anti-STAT3 antibodies. IL-6 secretion
by U266 was quantified with ELISA, following the differ-
ent cytokine treatments. For signalling analysis, a sand-
wich ELISA for mouse/human STAT3 was performed.
Cancer induction and treatments
To study the locoregional effect of GMME1 on tumor
development, 2 × 106 MSC-GFP were co-implanted
with 106 EG7 cells subcutaneously (sc) in immunocom-
petent C57Bl/6. For systemic efficacy of the fusokine,
106 EG7 cells were injected sc in immunocompetent
C57Bl/6 mice on one side, and an sc implant of conti-
gen-embedded gene-engineered MSCs (2 × 106 cells per
implant) was injected on the opposite flank as previously
described [14]. Tumor appearance and volume were
assessed every 48 hrs. To investigate the levels of circu-
lating GMME1 in treated mice, the sera were collected
at week 3 post-implantation of the neo-organoid and
screened by CCL2 ELISA to detect the CCL2 moiety of
the fusokine according to manufacturer’s instructions.
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GMME1-induced apoptosis of primary myeloma cells from
patients
Bone marrow aspirates from consenting myeloma
patients (n = 5) were processed as previously described
[16]. The IRB protocol was approved by Emory Univer-
sity. White blood cells in the marrow were isolated with
lymphocyte separation medium (Mediatech Inc., Mana-
ssas, VA), and stained with anti-human CD38 (PE),
CD45 (APC-Cy7), CD138 (FITC) (BD Bioscience, San
Jose, CA), or CCR2 (PerCP) (Biolegend, San Diego, CA)
antibodies or isotype controls (1:100 dilution). CD38
+CD45-CD138+ cells were considered as myeloma cells
[16]. Alternatively, white blood cells (106 cells/ml) were
cultured in RPMI 1640 medium with 10% FBS in pre-
sence of GMME1 (20 ng/ml). Condition medium with-
out GMME1 served as control. After 48-hour culture,
the cells were harvested and stained with anti-human
CD38, CD45 antibodies, and Annexin. FACS analysis
was performed on a BD FACSCanto II flow cytometer.
Data were analyzed with FlowJo 9.1 software.
Statistical analyses
P values were calculated using the ANOVA test, or
paired t-test in Figure Six F.
Results
Gene engineering of MSC as GMME1 biofactories
GMME1 is a fusion cytokine consisting of granulocyte
macrophage colony stimulating factor (GMCSF) in tan-
dem with N-terminal truncated monocyte chemotactic
protein-1 (MCP1 6-76) whose design and biochemical
analysis were previously reported and summarized in Fig-
ure 1A-B. We have also previously demonstrated that
gene- modified MSC can serve as robust cytokine biofac-
tories in vitro and in vivo [10,11,14,17-21]. We here sought
to exploit this platform to produce recombinant GMME1
in vivo. To obviate any confounding effect arising from
naturally produced CCL2 from MSC, MSC isolated from
CCL2-/-C57Bl/6 mice were engineered a polyclonal popu-
lation to produce secreted GMME1 as we previously pub-
lished [10,11]. MSC expressing GMME1 are CD44, CD73
and CD105 positive with no detectable CD45 (Figure 1C)
or CCR2 (Figure 1D) while retaining their capacity to dif-
ferentiate into adipocytes or osteoblasts (Figure 1E).
Supernatant analysis of these cells revealed a GMME1
secretion level at 30 ng per 1 million cells every 24 hrs
(Figure 1F). The conditioned media (CM) from these cells
was used as a source of GMME1 for in vitro experiments
and the engineered MSC were lately used as in vivo cell
factories for drug delivery.
GMME1 is tumoricidal to CCR2+ murine EG7 lymphoma
Since the truncated CCL2 domain of GMME1 is only active
on CCR2 [10,11], we determined the pharmacological effect
of the fusokine on the EG7 mouse lymphoma cell line
known to express CCR2 (Figure 2A). No proliferative
response was observed upon GMME1 treatment in contrast
to that seen with the use of CCL2 5-76 (Figure 2A). Since
we have previously shown that only GMME1 induces apop-
tosis on CCR2+ cells, PI/Annexin-V co-staining was per-
formed on GMME1-treated EG7 and revealed 30% cell
death following 48 hr treatment (Figure 2B) associated with
de novo expression of the pro-apoptotic BAX protein (Fig-
ure 2C). CCR2 is known to induce STAT3 phosphorylation;
a signalling molecule involved in survival, proliferation,
angiogenesis as well as immunosuppression [22]. Thus,
GMME1 was tested for its effect on STAT3 phosphoryla-
tion. A complete blockade was obtained within 5 min fol-
lowing treatment, an observation that was confirmed by
Western Blot (Figure 2D). To exclude any possible involve-
ment of the GMCSF moiety of the fusokine in inducing cell
death, monocytes were purified from CCR2-/- mice bone
marrow and treated with GMME1 versus control. No cell
death was detected on CCR2-/- monocytes as opposed to
WT control cells (Figure 2E).
GMME1 leads to EG7 growth suppression in vivo
To assess the anti-tumor properties of GMME1 in vivo,
we proceeded with the subcutaneous co-implantation of
2 × 106 MSC-GMME1 admixed with 106 EG7 lym-
phoma cells in immunocompetent C57Bl/6 mice and
monitored tumor growth relative to controls over time.
All mice implanted with MSC-GFP and EG7 developed
tumors by day 14 (Figure 3A upper left panel) with sig-
nificantly larger volumes when compared to EG7 tumors
cells alone (Figure 3A upper right panel). In contrast,
when GMME1-expressing MSC were coimplanted with
EG7 cells, a significant delay in tumor growth was
observed with 60% tumor-free mice (Figure 3A). A
more clinically relevant approach however, consists of
delivering GMME1 systemically rather than peritumo-
rally. Therefore, immunocompetent C57Bl/6 mice were
implanted subcutaneously with GMME1-secreting MSC
on one flank of the animal and the tumor cells on the
opposite flank. A substantial antitumor effect was
obtained with GMME1 since 20% of mice were tumor-
free with a significant tumor growth delay up to 3
weeks post-implantation of the GMME1-producing
MSC (Figure 3B). This therapeutic effect correlates with
the plasma levels of GMME1 at this time point (Figure
3C). Mice treated with GMME1 did not display evident
off target toxicity as ascertained by normal weights and
behaviour (data not shown).
GMME1 is tumoricidal to human CCR2+ U266 myeloma
cells
Mouse CCL2 is biologically active on human CCR2-
expressing cells [23]. In light of this inter-species
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Figure 1 Phenotype analysis. A. The amino acid sequence of GMME1. B. GMME1 Mechanism of Action. GMME1 is capable of blocking CCR2
homodimerization and recruitment of b-arrestin. As a result, various biochemical responses take place such as an increase in p38
phosphorylation while p44/42, AKT, STAT3 are inhibited. In addition, a strong Ca2+ influx s triggered leading to the activation of caspase 3 and
apoptosis. C. The phenotype of expanded C57BL/6 MSCs was analyzed by flow cytometry for various cell surface markers. D. An RT-PCR analysis
demonstrates that MSC do not express CCR2. E. MSC culture under adipogenic or osteogenic conditions leads to their differentiation.
Photographs were taken under light microscopy using a Contax167MT camera (Kyocera) with a 400 ISO film attached to an Axiovert25 Zeiss
microscope (Carl Zeiss) F. Following the retroviral transduction of MSC, the GFP expression levels was monitored by flow cytometry with GMME1
secretion level at 33 ng/106 cell/24 hrs as detected by ELISA (P < 0.05; n = 3/group).
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Figure 2 Pharmacological properties of GMME1 on EG7 tumor cells. A. Following the confirmation that EG7 cells express CCR2 by RT-PCR,
105 EG7 cells/well were cultured for 48 hrs in presence of increasing amounts of CCL2 5-76, CCL2 1-76 or GMME1 and the proliferative response
measured by MTT. CCL2 5-76, and to a lesser extent, CCL2 1-76 were capable of inducing the proliferation of EG7 cells as opposed to GMME1 (P
< 0.05; n = 6/group). B. Following the addition of 1.5 pmol of GMME1 on EG7 cells for 48 hrs (lower panel), a PI/Annexin-V co-staining
demonstrates that GMME1 leads to apoptosis induction (32% dead cells). None of the B16 cells, which are CCR2 null, were affected by the
addition of GMME1. C. EG7 cells cultured with GMME1 for 48 hrs induce de novo expression of the pro-apoptotic BAX protein. D. Following the
stimulation of EG7 cells for different time points, cell lysate was analysis by a pSTAT3 ELISA (P < 0.05; n = 6/group). The experiments were
repeated using the 5 min time point, then lysate was probed by WB. Total STAT3 was used as loading control. E. WT or CCR2-/- monocytes were
purified and cultured with 1.5 pmol of GMME1 for 48 hrs before a PI/Annexin-V co-staining. Even though 58% of WT monocytes died, no major
cell death was detected with CCR2-/- monocytes.
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Figure 3 Anti-tumor effect of GMME1-expressing CCL2-/-MSC. A. Subcutaneous injection of immuncompetent C57Bl/6 mice (n = 5/group)
with 106 EG7 cells alone or in combination with 2 × 106 MSC-GFP leads to the development of large tumors in all mice. The admixture of
GMME1-expressing MSC with EG7 tumor cells leads to a significant delay in EG7 growth with 60% of mice that remained tumor-free for over a
month (*P < 0.05). B. To assess the growth of EG7 cells in mice implanted with a neo-organoid expressing GFP vs the GMME1 fusokine,
immunocompetent C57Bl/6 mice (n = 5/group) were injected on one flank with contigen containing 2 × 106 MSC engineered to express GFP or
GMME1 followed by 106 EG7 cells on the opposite flank. Tumor volume and appearance was assessed every 48 hrs. A significant delay in tumor
growth was noticed (*P < 0.05). C. Three weeks post-contigen implantation, mice were bled and the sera tested using the CCL2 ELISA kit for
GMME1. All mice implanted with MSC expressing the fusokine GMME1 showed detectable levels as opposed to control MSC-GFP or mice
implanted with EG7 cells only (*P < 0.05).
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permissiveness, we assessed the pharmacological proper-
ties of mouse GMME1 on the human multiple myeloma
cell line U266, a CD19-/- human myeloma cell line
shown to express the plasma cell marker CD138 and
CCR2 (Figure 4A). U266 cells proliferated in a dose-
dependent manner using control N-terminus truncated
CCL2 5-76 whereas GMME1 led to a substantial prolif-
eration blockade (Figure 4B). To further confirm this
observation, PI/Annexin-V analysis following 48 hrs
GMME1 treatment led to 40% cell death by apoptosis
(Figure 4C). U266 growth and proliferation depends on
the autocrine secretion of human IL6, which leads to
pSTAT3 [22]. Since we have previously shown that
GMME1 inhibits STAT3 phosphorylation in EG7 lym-
phoma cells, we assessed the level of STAT3 activation
first by ELISA at different time points and documented
a complete loss of activation following 10 min of
GMME1 treatment, an observation that was confirmed
by immunoblot (Figure 4D left panels). These data cor-
relate with the loss of human IL6 secretion by U266
(Figure 4D right panel) due to cell death induced by
GMME1.
GMME1 is tumoricidal to mouse and human CCR2+
medulloblastoma cells
Human glial tumors are known to express CCR2,
though the biological significance of this observation is
unknown [24]. We tested whether medullobalstoma cell
lines also possess this feature. We found that both
mouse (PS125) and human (Daoy) medulloblastoma cell
lines expressed CCR2, and this expression was enhanced
by PDGF, a known pro-oncogenic stimulus for this
malignancy as shown in Figure 5A and 5D, respectively
[13]. We tested whether GMME1 was tumoricidal to
these medulloblastoma cell lines and observed that a
substantial fraction of tumors treated with GMME1 died
by apoptosis as opposed to control groups (53% vs 17%
for the mouse cell line in Figure 5B, and 22.3% vs 2.5%
for the human cell line in Figure 5E). This pro-apoptotic
effect was also shown to be GMME1 dose-dependent
(Figure 5C and 5F respectively). Moreover, we con-
firmed that affinity-purified GMME1 protein possesses
strong tumoricidal activity on human medulloblastoma
cells (Figure 5F).
GMME1 induced apoptosis of primary multiple myeloma
cells
Human multiple myeloma is a clonal plasma cell char-
acterized by resistance of apoptosis by expression of a
panel of anti-apoptotic molecules [16]. We have pre-
viously showed that the multiple myeloma cell line
U266 expressed CCR2 and is susceptible to GMME1-
induced apoptosis (Figure 4A-C). Thus, we predict that
GMME1 protein would trigger apoptosis in primary
myeloma cells collected from consenting patients. Profil-
ing of CD38+CD138+CD45- myeloma cells (Figure 6A-B)
isolated from patients by FACS confirmed the expres-
sion of the chemokine receptor CCR2 (Figure 6B-C).
Subsequent treatment of primary myeloma cells with
GMME1 (Figure 6E-F) for 48 hours in vitro led to sub-
stantial and significant apoptosis in comparison with the
condition medium control (Figure 6D, F).
Discussion
Interfering with the CCL2/CCR2 ligand/receptor path-
way may be of meaningful use in cancer therapy and we
here tested whether the CCR2-selective, pro-apoptotic
effects of GMME1 we observed previously [10,11] could
be utilized in such a setting. We tested the effect of
GMME1 on the CCR2-expressing murine EG7 lymphoid
and the human U266 myeloma cell lines in vitro. We
found that GMME1 induces their death as previously
observed in autoreactive immune cells [10,11]. A com-
mon mechanistic denominator is suppression of phos-
phorylation of STAT3 and induction of pro-apoptotic
effectors such as BAX (none of the remaining Bcl-2
pro-apoptotic molecules were induced). We may specu-
late that the GMME1/CCR2 interaction leads to recruit-
ment of a GPCR-linked phosphatase or activates an
alternate signalling pathway interfering or competing
with STAT3 activation. We have previously shown that
delivery of GMME1 via a gene-enhanced cellular plat-
form to mice ill with EAE or arthritis, led to immune
suppression and clinical remission and we here found
that the same platform could serve to treat mice
implanted with CCR2+ EG7 lymphoma. These data
demonstrate that GMME1’s tumoricidal properties can
be replicated in vivo as well, demonstrating that its pro-
apoptotic effects are unaffected by tumor/host
interactions.
Intriguingly, non-hematological epithelial malignan-
cies, such as prostate cancer, have been found to be
addicted to CCL2 for their survival and malignant beha-
viour [25,26]. Furthermore, an astonishingly high pro-
portion of primary human glial tumors overexpress
CCR2 (whilst normal brain structures do not), suggest-
ing possibly a similar mechanistic bonding to CCL2
[24]. We here demonstrate that medulloblastoma cells
of both murine and human origins express CCR2 and
are susceptible to GMME1-mediated apoptosis in vitro.
There have been meaningful attempts at targeting the
CCL2/CCR2 pathway for cancer therapy. For example, it
was believed that neutralizing CCL2 would be of benefi-
cial potential for the control of CCR2-expressing tumor
cells. Unexpectedly, the systemic administration of anti-
CCL2 antibodies in prostate cancer mouse models only
slightly attenuated the proliferation of tumor cells likely
due to the “rescue” of the CCR2+ tumor cells by
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Figure 4 Pharmacological properties of GMME1 on human U266 tumor cells. A. U266 cells were analyzed by flow cytometry and were
negative for the expression of CD19 while CD138 and CCR2 were detected. B. 105 U266 cells were cultured with increasing amounts of CCL2 5-
76, CCL2 1-76 or GMME1 and the proliferative response measured by MTT. CCL2 5-76 was capable of inducing U266 proliferation whereas
GMME1 completely suppressed the proliferative response (P < 0.05; n = 6/group). C. Using 1.5 pmol of GMME1 on U266 cells for 48 hrs, a PI/
Annexin-V co-staining demonstrates that GMME1 leads to apoptosis (42% cell death). D. A similar set-up was used for the assessment of STAT3
activation on U266 cells. Following the stimulation of U266 cells using different time points, cell lysate was analysis by a pSTAT3 ELISA. Since
STAT3 is inhibited as of 10 min following GMME1 addition on U266 cells, the experiment was repeated at this time point then the lysate was
probed by WB. Total STAT3 was used as loading control. To further confirm the inhibitory effect of GMME1 on these cells, the U266 conditioned-
media was collected following 48 hrs post-treatment with the different test conditions and analyzed using a human IL-6 ELISA kit. No detectable
levels of human IL6 could be observed in the GMME1 group as opposed to the remaining test conditions (*P < 0.05; n = 6/group).
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alternate chemokine ligands [27]. As an alternative,
antagonizing CCR2 was suggested as an approach with
wider applicability for cancer therapy. A group has
investigated the use of a dominant negative CCL2 con-
struct lacking 2-8 amino acids at its N-terminus (7ND)
targeting CCR2 in a melanoma mouse model [28]. This
study demonstrated modest effects in vivo most likely
because of low expression levels and non-efficient deliv-
ery method [28].
In contrast, GMME1 is radically distinct in its tumori-
cidal CCR2-targeted function since it is not simply a
decoy or passive dominant negative, but rather is an
active ligand leading to receptor-mediated activation of
apoptosis. In essence, GMME1 behaves as an entirely
novel chemokine, co-opting CCR2 signaling machinery
to compel CCR2+ malignant cells to enter apoptosis.
This mechanism of action is attractive as a non-cross-
resistant cancer-killing pathway that may complement
current therapies for resistant or relapsing CCR2+ hema-
tological malignancies, pediatric medulloblastoma or
human multiple myeloma, and other CCR2+ tumors as
well. The fact that GMME1 protein can significantly
induce cell death of CCR2+ primary myeloma from
patients indicates its potential clinical utility.
It should be noted however that CCR2-mediated in
vitro killing of tumor cells does not exclude a possibility
that in vivo anti-tumor activity of GMME1 is mediated
at least in part by killing of CCR2-positive cells within
the tumor microenvironment such as macrophages,
which are known to express CCR2 and to support
Figure 5 Pharmacological properties of GMME1 on CCR2+ medulloblastoma cells. A. Confirmation of CCR2 expression on mouse
medulloblastoma cell line PS125. B. PS125 cells were seeded in 6-well plates (104 cells/well) and cultured with CCL2-/- or GMME1 CM. After 48
hrs, apoptosis was measured by Annexin-V/PI staining. C. To further see a dose-response effect, the same experiment was repeated using 3
different concentrations and cell death was analyzed (P < 0.05; n = 3/group). D. Human medulloblastoma cells (Daoy) were analyzed by WB to
confirm the presence of CCR2 on cell surface. E. Human medulloblastoma cells were treated with GMME1 as described in B. Cell apoptosis was
measured by Annexin-V/PI staining after 48 hrs culture. F. Human medulloblastoma cells were cultured in presence of GMME1 in condition
medium or affinity-purified GMME1 protein. Cell growth was measured by MTT assay. (*P < 0.05; **P < 0.01; n = 3/group).
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tumor growth. We have previously demonstrated [10]
that CCR2+ macrophages harvested from C57BL/6 mice
and exposed to GMME1 died by apoptosis 24 h later as
shown by activation of caspase-3 as well as annexin-V/
PI co-staining. Such macrophage-depleting capacity of
the fusokine does not involve the GMCSF moiety since
CCR2-/- monocytes expressing the GMCSFR do not die
following GMME1 treatment. This set of data suggests
that GMME1 can theoretically deplete macrophages in
tumour that can potentially play a role in angiogenesis
and thus promoting tumor growth.
Conclusions
In conclusion, we have previously demonstrated that the
use of GMME1 fusokine could be of significant thera-
peutic value for depletion of CCR2 autoreactive lympho-
myeloid cells. We here further demonstrate that
GMME1 also represents a conceptually novel biological
approach for eradication of CCR2-expressing malignant
cells without noticeable off-target toxicity to the host.
The use of innovative chimeric CC-ligand fusokines
could serve as a prototype strategy seeking to selectively
deplete cancers whose proliferation and survival depends
upon CCR-driven signalling.
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